
Acute and postacute sequelae associated with SARS-CoV-2 reinfection

In the format provided by the
authors and unedited


Supplementary Information

Outcomes of SARS-CoV-2 Reinfection


Table of Contents	Page
Supplementary Figures	
Supplementary Figure 1: Standardized mean differences between SARS-CoV-2 reinfection and no reinfection before and after weighting.	2
Supplementary Figure 2: Timeline of analyses for risk and burden assessment comparing reinfection to no reinfection.	3
Supplementary Figure 3: Timeline of analyses for risk and burden assessment by number of infections.	4
Supplementary Tables	
Supplementary Table 1: Demographic and health characteristics of those with non-infected control group, no SARS-CoV-2 reinfection, and SARS-CoV-2 reinfection.	Excel sheet
Supplementary Table 2: Demographic and health characteristics by SARS-CoV-2 reinfection status after weighting.	Excel sheet
Supplementary Table 3: Risk and 6-month burden of death, hospitalization, at least one sequela, and sequelae by organ system in SARS-CoV-2 reinfection compared to those with no SARS-CoV-2 reinfection.	Excel sheet
Supplementary Table 4: Risk and 6-month burden of death, hospitalization, at least one sequela, and sequelae by organ system in SARS-CoV-2 reinfection compared to no SARS-CoV-2 reinfection by vaccination status at time of reinfection.	Excel sheet
Supplementary Table 5: Risk and 6-month burden of death, hospitalization, at least one sequela, and sequelae by organ system in SARS-CoV-2 reinfection compared to no SARS-CoV-2 reinfection by time since reinfection.	Excel sheet
Supplementary Table 6: Demographic and health characteristics in those with one infection, two infections, three infections, and the non-infected control.	Excel sheet
Supplementary Table 7: Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with one SARS-CoV-2 infection compared to the non-infected control.	Excel sheet
Supplementary Table 8: Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with two SARS-CoV-2 infections compared to the non-infected control.	Excel sheet
Supplementary Table 9: Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with three or more SARS-CoV-2 infections compared to the non-infected control.	Excel sheet
Supplementary Table 10: Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with two SARS-CoV-2 infections compared to those with one SARS-CoV-2 infection.	Excel sheet
Supplementary Table 11: Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with three or more SARS-CoV-2 infections compared to those with one SARS-CoV-2 infection.	Excel sheet

<u>Supplementary Table 12</u> Risk and one year burden of hospitalization, at least one sequela, and sequelae by organ system in those with three or more SARS-CoV-2 infections compared to those with two SARS-CoV-2 infections.	Excel sheet
<u>Supplementary Table 13</u> Organ system disorder definitions	Excel sheet

Supplementary Figure 1: Standardized mean differences between SARS-CoV-2 reinfection and those without reinfection (only one infection) before and after weighting.



Supplementary Figure 2: Timeline of analyses for risk and burden assessment comparing reinfection to first infection. Timelines are plotted for the first infection and reinfection cohorts. Cohort participant characteristics were balanced at T_0 , the date of their first infection. Risk and burdens were then estimated in the 180 days following T_1 , the date of reinfection, in comparison to a similar T_1 in the no reinfection group.



Supplementary Figure 3: Timeline of analyses for risk and burden assessment by number of infections. Timelines are plotted for the non-infected control, and in those with one, two, and three or more infections. Cohort participant characteristics were balanced at T_0 , the date of their first infection or a randomly assigned T_0 in the non-infected control group. Risk and burdens were then estimated in the 360 days following the acute phase of the first infection (or corresponding time in the non-infected control group).

